Literature DB >> 15957176

Novel rearrangement of chromosome band 22q11.2 causing 22q11 microdeletion syndrome-like phenotype and rhabdoid tumor of the kidney.

R Wieser1, B Fritz, R Ullmann, I Müller, M Galhuber, C T Storlazzi, A Ramaswamy, H Christiansen, N Shimizu, H Rehder.   

Abstract

The 22q11.2 microdeletion syndrome is the most frequent microdeletion syndrome in humans, yet its genetic basis is complex and is still not fully understood. Most patients harbor a 3-Mb deletion (typically deleted region [TDR]), but occasionally patients with atypical deletions, some of which do not overlap with each other and/or the TDR, have been described. Microduplication of the TDR leads to a phenotype similar, albeit not identical, to the deletion of this region. Here we present a child initially suspected of having 22q11 microdeletion syndrome, who in addition developed a fatal malignant rhabdoid tumor of the kidney. Detailed cytogenetic and molecular analyses revealed a complex de novo rearrangement of band q11 of the paternally derived chromosome 22. This aberration exhibited two novel features. First, a microduplication of the 22q11 TDR was associated with an atypical 22q11 microdeletion immediately telomeric of the duplicated region. Second, this deletion was considerably larger than previously reported atypical 22q11 deletions, spanning 2.8 Mb and extending beyond the SMARCB1/SNF5/INI1 tumor suppressor gene, whose second allele harbored a somatic frameshift-causing sequence alteration in the patient's tumor. Two nonallelic homologous recombination events between low-copy repeats (LCRs) could explain the emergence of this novel and complex mutation associated with the phenotype of 22q11 microdeletion syndrome. (c) 2005 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2005        PMID: 15957176     DOI: 10.1002/humu.20195

Source DB:  PubMed          Journal:  Hum Mutat        ISSN: 1059-7794            Impact factor:   4.878


  7 in total

1.  Congenital anomalies and rhabdoid tumor associated with 22q11 germline deletion and somatic inactivation of the SMARCB1 tumor suppressor.

Authors:  George Toth; Claudia B Zraly; Tricia L Thomson; Carolyn Jones; Shawn Lapetino; Jonathan Muraskas; Jiwang Zhang; Andrew K Dingwall
Journal:  Genes Chromosomes Cancer       Date:  2011-03-15       Impact factor: 5.006

Review 2.  Genetics of pediatric renal tumors.

Authors:  Brigitte Royer-Pokora
Journal:  Pediatr Nephrol       Date:  2012-03-30       Impact factor: 3.714

3.  Molecular characterization of the pediatric preclinical testing panel.

Authors:  Geoffrey Neale; Xiaoping Su; Christopher L Morton; Doris Phelps; Richard Gorlick; Richard B Lock; C Patrick Reynolds; John M Maris; Henry S Friedman; Jeffrey Dome; Joseph Khoury; Timothy J Triche; Robert C Seeger; Richard Gilbertson; Javed Khan; Malcolm A Smith; Peter J Houghton
Journal:  Clin Cancer Res       Date:  2008-07-15       Impact factor: 12.531

4.  High-density single nucleotide polymorphism array analysis in patients with germline deletions of 22q11.2 and malignant rhabdoid tumor.

Authors:  Eric M Jackson; Tamim H Shaikh; Sridharan Gururangan; Marilyn C Jones; David Malkin; Sarah M Nikkel; Craig W Zuppan; Luanne M Wainwright; Fan Zhang; Jaclyn A Biegel
Journal:  Hum Genet       Date:  2007-05-31       Impact factor: 4.132

Review 5.  A deletion and a duplication in distal 22q11.2 deletion syndrome region. Clinical implications and review.

Authors:  Luis Fernández; Julián Nevado; Fernando Santos; Damià Heine-Suñer; Victor Martinez-Glez; Sixto García-Miñaur; Rebeca Palomo; Alicia Delicado; Isidora López Pajares; María Palomares; Luis García-Guereta; Eva Valverde; Federico Hawkins; Pablo Lapunzina
Journal:  BMC Med Genet       Date:  2009-06-02       Impact factor: 2.103

6.  Breakpoint Associated with a novel 2.3 Mb deletion in the VCFS region of 22q11 and the role of Alu (SINE) in recurring microdeletions.

Authors:  Raihan K Uddin; Yang Zhang; Victoria Mok Siu; Yao-Shan Fan; Richard L O'Reilly; Jay Rao; Shiva M Singh
Journal:  BMC Med Genet       Date:  2006-03-02       Impact factor: 2.103

7.  Mapping the deletion endpoints in individuals with 22q11.2 deletion syndrome by droplet digital PCR.

Authors:  Vicki J Hwang; Dianna Maar; John Regan; Kathleen Angkustsiri; Tony J Simon; Flora Tassone
Journal:  BMC Med Genet       Date:  2014-10-14       Impact factor: 2.103

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.